![Jan Thirkettle](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jan Thirkettle
Vorstandsvorsitzender bei Transine Therapeutics Ltd.
Aktive Positionen von Jan Thirkettle
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Vorstandsvorsitzender | 05.07.2021 | - |
Karriereverlauf von Jan Thirkettle
Ehemalige bekannte Positionen von Jan Thirkettle
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
FREELINE THERAPEUTICS HOLDINGS PLC | Corporate Officer/Principal | - | - |
Freeline Therapeutics Ltd.
![]() Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Vorstandsvorsitzender | 01.07.2017 | - |
Corporate Officer/Principal | 01.07.2017 | - |
Ausbildung von Jan Thirkettle
University of Oxford | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 5 |
Operativ
Chief Executive Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Freeline Therapeutics Ltd.
![]() Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Freeline Therapeutics Holdings Plc
![]() Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Health Technology |
- Börse
- Insiders
- Jan Thirkettle
- Erfahrung